SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb on concerns that Middle East shipping and energy-infrastructure attacks could disrupt supply. Traders are split between betting the geopolitical risk premium persists and expecting it to unwind if shipping normalizes or diplomacy advances, while many warn elevated oil could add to inflation pressure and weigh on broader markets.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Concerns about CoreWeaves debt-heavy expansion and borrowing costs, amplified by HSBCs warning that financing risks and slower AI demand could pressure growth, dominate the discussion. Bears question whether its backlog can offset funding needs, while bulls point to AI-compute demand and see the selloff as a buying or short-squeeze opportunity.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

A prolonged, steep selloff has fueled criticism of USA Rare Earths new CEO and board, with investors complaining about limited communication and questioning execution, cash burn, and potential share dilution. Some traders see the decline as an opportunity, citing the companys strategic role in domestic rare-earth supply chains and government backing, while others remain bearish amid sector-wide weakness.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a steep selloff to new lows, with traders linking the pressure to weakening Trump approval and approaching midterms, as well as concerns about Truth Social and the companys limited operating business. Some view the pending TAE fusion deal as a diversification opportunity, but note that it has not yet transformed the company.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders pointing to successive lockup expirations and insider selling as potential supply pressure, alongside a TD Cowen price-target cut and concerns about valuation, growth and customer concentration. Bulls argue the shares are oversold and cite the companys AI hardware and backlog, while bears expect more downside; the discussion is predominantly bearish.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

Barclays downgrade and warning about commercial execution risks, particularly delays in securing a definitive TVA agreement, are driving concern around NuScales steep selloff. Traders are split between those worried the company cannot turn its reactor technology into firm projects and buyers who see the cash position and long-term nuclear demand as reasons to hold or accumulate.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is under pressure after its Q3 earnings beat failed to overcome disappointment with a full-year profit outlook that was narrowed without raising its midpoint, alongside weaker U.S. deliveries and market share. Traders debate whether the new buyback and stronger cash-flow outlook offset the cautious guidance, with some calling the selloff excessive.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces agreement to acquire customer-engagement platform Braze is the main catalyst, with the deal expected to expand Marketing Cloud and its AI capabilities. Traders are weighing the strategic fit against the sizable cash outlay, and some are reacting negatively to CRMs weakness around the announcement.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs quarterly earnings beat and raised 2026 outlook are drawing attention, but shares are falling as traders weigh higher costs, weaker free cash flow and a loss in its insurance business against strong aerospace demand. Some see the report as a solid result, while others question whether services growth and margins can justify expectations.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention after a broad quarterly earnings beat, raised full-year guidance, and a record backlog, reflecting strong defense and commercial aerospace demand. Traders are largely upbeat about the results, though some question how much of the guidance increase reflects cost recoveries and point to the shares weak reaction despite the strong report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock

Revealing a significant insider sell on August 26, Stephen P Robertson, Chief Legal Officer at Aurinia Pharmaceuticals (NASDAQ:AUPH), as per the latest SEC filing.
What Happened: A Form 4 filing with the U.S. Securitiesread more...

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.read more...

AUPH Stock Rallies 6% After-Hours  — Here’s Why 

Equity

Aurinia said it and its U.S. subsidiary reached an agreement with Teva Pharmaceuticals resolving patent infringement litigation tied to Teva’s application to sell a generic version of LUPKYNIS.  


Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, Aurinia) have entered into a settlement agreement with Teva Pharmaceuticals Inc. (Teva) to resolve patent infringement litigation relating to Tevas filing of an...

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +47.37% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three and six months ended June 30, 2026, total revenue was $83.2 million and...

NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates

NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.33% and -45.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?

Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150...

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Under the deal, Teva agreed that two of Aurinia’s key U.S. patents, expiring in December 2037, are valid, enforceable, and would be infringed by its generic product.</li><li>Teva may not launch its version in the United States before December 7, 2036.</li><li>LUPKYNIS is Aurinia’s main commercial product, approved for treating adults with active lupus nephritis.</li></ul>Shares of Aurinia Pharmaceuticals Inc (AUPH) jumped as much as 6% after-hours on Wednesday after the company announced a patent settlement that delays a potential generic version of its key drug until late 2036.The stock gained 6% during regular trading and was trading 3% higher after-hours at the time of writing.<h2 class="st-heading-2">Settlement Details</h2>Aurinia said it and its U.S. subsidiary reached an agreement with Teva Pharmaceuticals (TEVA) resolving patent infringement litigation tied to Teva’s application to sell a generic version of LUPKYNIS. &nbsp;Under the deal, Teva agreed that two of Aurinia’s key U.S. patents, expiring in December 2037, are valid, enforceable, and would be infringed by its generic product. Teva may not launch its version in the United States before December 7, 2036, unless certain limited contingencies occur earlier, Aurinia said. Any launch also requires FDA approval. &nbsp;By locking in exclusivity against a major challenger until December 2036, Aurinia extends the period during which it can sell LUPKYNIS without direct competition from Teva.<h2 class="st-heading-2">Why The Litigation Matters</h2>LUPKYNIS is Aurinia’s main commercial product, approved for treating adults with active lupus nephritis, a serious kidney complication of lupus. Multiple companies filed applications in 2025 seeking to sell cheaper copies before the patents expire. &nbsp;Litigation against other generic makers—including Dr. Reddy’s, Hikma, Sandoz, Zydus, and others—continues in federal court in New Jersey.<h2 class="st-heading-2">Other Near-Term Catalysts And Recent Progress</h2>Aurinia continues to post solid commercial growth while expanding its pipeline. In its second-quarter results reported earlier this month, the company delivered total revenue of $83.2 million, up 19% year-over-year, and LUPKYNIS net product sales of $79.4 million.Net income rose 74% to $37.4 million, and cash and investments stood at $443.1 million after share repurchases. Management reiterated full-year 2026 guidance of $315–$325 million in total revenue and $305–$315 million in LUPKYNIS sales.On the clinical side, Aurinia recently started the PRESERVE study to test LUPKYNIS in combination with other approved lupus drugs to determine whether a multi-drug approach can improve kidney outcomes. The company has also moved its next pipeline candidate, aritinercept, into clinical development across four autoimmune diseases, creating potential longer-term growth opportunities beyond LUPKYNIS.<h2 class="st-heading-2">How Did AUPH Retail Traders React?</h2>On Stocktwits, retail sentiment around AUPH stock jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.Stocktwits users cheered the settlement and now expect other litigations to also yield positive outcomes for Aurinia.<stembedurl>https://stocktwits.com/US_Bull/message/662343987</stembedurl><stembedurl>https://stocktwits.com/paperjam/message/662341041</stembedurl>Another user noted that Aurinia is now looking “increasingly attractive as a buyout target.” The user further expects the company to be acquired at a price of up to $30 per share.<stembedurl>https://stocktwits.com/Marcx123/message/662347616</stembedurl><a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> has gained 1% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/iova-stock-hits-new-52-week-high-as-shares-jump-14-what-drove-the-rally/cZYduAxRJlr">IOVA Stock Hits New 52-Week High As Shares Jump 14% — What Drove The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

Under the deal, Teva agreed that two of Aurinia’s key U.S. patents, expiring in December 2037, are valid, enforceable, and would be infringed by its generic product.Teva may not launch its version in the United States before December 7, 2036.LUPKYNIS is A

AUPH Stock Rallies 6% After-Hours  — Here’s Why

iShares Russell 2000 ETF

Teva- Pharmaceutical Industries Ltd. - ADR

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$16.49
Prev Close	$16.51
Open	$16.54
Dividend Yield	0.00%
50-Day Moving Average	$16.24
Beta	0.76
Avg. Volume	819,438.92
PE Ratio	7.21

52-Week High	$19.25
52-Week Low	$11.48
Market Capitalization	$2.19B
EPS (Annual)	$2.07
Price to Book	3.56
Revenue Per Employee	$2.21M

Feed

News

Sentiment

Earnings

Fundamentals

Info

AUPH Fundamentals